Compare TRUP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | IVA |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2014 | N/A |
| Metric | TRUP | IVA |
|---|---|---|
| Price | $28.90 | $6.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $45.50 | $16.20 |
| AVG Volume (30 Days) | ★ 530.0K | 518.7K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 295.65 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,439,305,000.00 | N/A |
| Revenue This Year | $12.42 | N/A |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $64.22 | ★ N/A |
| Revenue Growth | ★ 11.95 | N/A |
| 52 Week Low | $27.30 | $2.70 |
| 52 Week High | $57.35 | $7.98 |
| Indicator | TRUP | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 63.61 |
| Support Level | $27.30 | $5.95 |
| Resistance Level | $34.42 | $6.37 |
| Average True Range (ATR) | 1.57 | 0.30 |
| MACD | -0.25 | -0.03 |
| Stochastic Oscillator | 24.44 | 98.00 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.